Critical Comparison: NKGen Biotech (NKGN) versus Its Peers

Earnings and Valuation

This table compares NKGen Biotech and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NKGen Biotech	$80,000.00	-$82.94 million	-0.05
NKGen Biotech Competitors	$554.70 million	-$35.55 million	-24,306.50

NKGen Biotech’s peers have higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares NKGen Biotech and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NKGen Biotech Competitors	-4,958.92%	-160.22%	-43.06%

Volatility and Risk

NKGen Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, NKGen Biotech’s peers have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Institutional and Insider Ownership

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 74.7% of NKGen Biotech shares are owned by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NKGen Biotech beats its peers on 5 of the 9 factors compared.

NKGen Biotech Company Profile

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.